Choices and goals in the treatment of the diabetic hypertensive patient
- 21 Downloads
The number of people living in the United States who have diabetes and high blood pressure is over 11 million and rising. Together, these two diseases are devastating to the whole body if not aggressively controlled. The tight recommendations put forth by the Joint National Committee VI for better control of blood pressure and control of proteinuria have helped diminish further organ failure in patients with hypertension and diabetes. Combination therapy has been found to be very effective, and one arm should be an angiotensin converting enzyme inhibitor.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 6.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998, 317:703–713. Classic paper that clearly shows that once end-organ injury is present, it is blood pressure control, not glucose control, that will reduce cardiovascular events.Google Scholar
- 8.Bakris GL, Williams M, Dworkin L, et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36:646–661. This paper presents the National Kidney Foundation position paper on control of blood pressure to reduce renal disease progression and cardiovascular events.PubMedGoogle Scholar
- 9.Maschio G, Alberti D, Janin G, et al.: Effect of the angiotensinconverting- enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting- Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334:939–945.PubMedCrossRefGoogle Scholar
- 10.Ruggenenti P, Perna A, Gherardi G, et al.: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy [see comments]. Lancet 1998, 352:1252–1256.PubMedCrossRefGoogle Scholar
- 11.Ratzmann KP, Raskovic M, Thoelke H: Significance of proteinuria and hypertension in the prognosis of type 1 diabetes. Results of a 10-year follow-up study on micro- and macrovascular disease mortality. Deutsch Med Wochensch 1989, 114:1311–1315.Google Scholar
- 16.Smith AC, Toto R, Bakris GL: Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998, 54:889–896. This paper focuses on the mechanism of why CCBs are different with regard to antiproteinuric effects in diabetes.PubMedCrossRefGoogle Scholar
- 18.The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413–2446. This paper summarizes guidelines for cardiovascular and renal risk reduction as of 1997.Google Scholar
- 19.1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999, 17:151–183.Google Scholar
- 20.McAlister FA, Campbell NR, Zarnke K, et al.: The management of hypertension in Canada: a review of current guidelines, their shortcomings and implications for the future. Can Med Asoc J 2001, 164:517–522.Google Scholar
- 22.Bakris GL: Maximizing cardio-renal benefits: achieve blood pressure goals. J Clin Hypertens 1999, 1:141–148.Google Scholar